Considering BCG vaccination to reduce the impact of COVID-19
- 1 May 2020
- journal article
- letter
- Published by Elsevier BV in The Lancet
- Vol. 395 (10236), 1545-1546
- https://doi.org/10.1016/s0140-6736(20)31025-4
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Defining trained immunity and its role in health and diseaseNature Reviews Immunology, 2020
- Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG RevaccinationThe New England Journal of Medicine, 2018
- BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained ImmunityCell Host & Microbe, 2018
- Early BCG-Denmark and Neonatal Mortality Among Infants Weighing <2500 g: A Randomized Controlled TrialClinical Infectious Diseases, 2017
- Non-specific effects of vaccines: plausible and potentially important, but implications uncertainArchives of Disease in Childhood, 2017
- Harnessing the beneficial heterologous effects of vaccinationNature Reviews Immunology, 2016
- Influence of BCG vaccine strain on the immune response and protection against tuberculosisFEMS Microbiology Reviews, 2008
- Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-guérin).1976
- The role of the reticuloendothelial system in the host reaction to neoplasia.1961